EU COVID-19 Rapid Antigen Tests Common List Inclusion of YHLO GLINE-2019-nCoV Ag

2021-12-09

Summary:

After being successfully granted official approval by the German PEI, YHLO’s rapid antigen test product GLINE-2019-nCoV Ag is officially listed on the EU COVID-19 Rapid Antigen Tests Common List on 8th December, 2021.

Regulated by the EU Health Security Committee (HSC), this common list is intended to recognize COVID-19 rapid antigen tests which are considered appropriate for use in the context of the situations described in the Council Recommendation, that are in line with EU countries’ testing strategies after series of comprehensive evaluations.

The recognition from the HSC common list is a credible proof that, YHLO’s rapid antigen test product is well-qualified to be applied in the COVID-19 pandemic control measure. Just as GLINE-2019-nCoV Ag can effectively detect the recently-emerged SARS-CoV-2 variant Omicron, as well as other Variants of Concern, YHLO’s product is capable of facing upcoming challenges with deliberate product design and assured quality.

YHLO is always pursuing to provide better solutions for global public health. With the mission of “Focus on healthcare, better life with technology”, YHLO will continue to provide reliable, high-quality healthcare innovations and services worldwide to improve human well-being.

 

 

图片无替代文字

 

图片无替代文字

Language
Search
亚辉龙

Join Us

关注我们

Wechat

Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China

Follow YHLO

wechatwechat wechat wechat wechat

© 2020  Shenzhen YHLO Biotech Co., Ltd.  All rights reserved.  粤ICP备17105123号